Coya Therapeutics, Inc. – NASDAQ:COYA

Add to watchlist

$5.94

+0.02

+0.34%

Market closed

Open in 2 days

-20.96%

month

-20.96%

quarter

-21.07%

year

Market Cap	88.21M
Enterprise value	N/A

P/E	N/A
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	N/A
PEG ratio	N/A
EPS	-0.91

Revenue	N/A
EBITDA	-10.24M
Income	-10.30M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Coya Therapeutics, Inc. (NASDAQ:COYA): Profit margin
Jun 2023	0	-3.09M
Sep 2023	0	-3.42M
Dec 2023	6.00M	1.26M	21.09%
Mar 2024	126.83K	-5.05M	-3982.96%

Coya Therapeutics Financials Estimate

Q Y

Coya Therapeutics, Inc. (NASDAQ:COYA): Analyst Estimates
Mar 2024	126.83K	-5.05M	-3982.96%
Sep 2025	6.00M	-8.62M	-143.76%
Oct 2025	900K	-6.93M	-771.08%
Dec 2025	900K	-7.44M	-827.31%

Analysts Price target
Financials & Ratios estimates

Coya Therapeutics, Inc. (NASDAQ:COYA): Earnings per share (EPS)
2023-11-08	-0.37	-0.34
2024-03-19	0.26	0.15
2024-05-09	-0.3	-0.35

Coya Therapeutics, Inc. (NASDAQ:COYA): Debt to assets
Jun 2023	14469235	1.22M	8.44%
Sep 2023	11895426	1.80M	15.19%
Dec 2023	41273524	5.62M	13.63%
Mar 2024	37542720	5.00M	13.32%

Coya Therapeutics, Inc. (NASDAQ:COYA): Cash Flow
Jun 2023	-2.86M	-350K	0
Sep 2023	-2.21M	0	0
Dec 2023	-2.24M	-193.18K	24.17M
Mar 2024	2.14M	-25K	1.24M

Coya Therapeutics alternative data

Coya Therapeutics, Inc. (NASDAQ:COYA): Employee count
Aug 2023	6
Sep 2023	6
Oct 2023	6
Nov 2023	6
Dec 2023	6
Jan 2024	6
Feb 2024	6
Mar 2024	8
Apr 2024	8
May 2024	8
Jun 2024	8
Jul 2024	8

Coya Therapeutics
Hedge Funds Holdings Q1 2023

22.06% -20.08%

of COYA is owned by hedge funds

5 +1

hedge funds hold COYA stock

571.44K -519.97K

shares is hold by hedge funds

COYA hedge funds holdings changes

Coya Therapeutics
Insider Trading

Coya Therapeutics, Inc. (NASDAQ:COYA): Insider trades (number of shares)
Period	Buy	Sel
Jan 2023	88500	0
Aug 2023	1000	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	22 Aug 2023	LEE ANN director director	Common Stock, par value $0.0001 per share	1,000	$3.62	$3,620
Purchase	3 Jan 2023	GOLDSTEIN DOV A MD director director	Warrant to Purchase Common Stock	5,000	$7.5	$37,500
Purchase	3 Jan 2023	GOLDSTEIN DOV A MD director director	Common Stock, par value $0.0001 per share	10,000	N/A	N/A
Purchase	3 Jan 2023	VILLALOBOS ANABELLA director director	Warrant to Purchase Common Stock	5,000	$7.5	$37,500
Purchase	3 Jan 2023	VILLALOBOS ANABELLA director director	Common Stock, par value $0.0001 per share	10,000	N/A	N/A
Purchase	3 Jan 2023	GARREN HIDEKI director director	Warrant to Purchase Common Stock	1,000	$7.5	$7,500
Purchase	3 Jan 2023	GARREN HIDEKI director director	Common Stock, par value $0.0001 per share	2,000	N/A	N/A
Purchase	3 Jan 2023	SNYDER DAVID S officer: Chief Financial Officer officer: Chief Financial Officer	Warrant to Purchase Common Stock	3,500	$7.5	$26,250
Purchase	3 Jan 2023	SNYDER DAVID S officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock, par value $0.0001 per share	7,000	N/A	N/A
Purchase	3 Jan 2023	HEPNER ADRIAN officer: Chief Medical Officer officer: Chief Medical Officer	Warrant to Purchase Common Stock	5,000	$7.5	$37,500

COYA insider trading transactions

Coya Therapeutics
Latest News

Wednesday, 18 December 2024
08:15	Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD)	businesswire.com
Monday, 25 November 2024
08:15	Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference	businesswire.com
Wednesday, 6 November 2024
08:00	Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results	businesswire.com
Friday, 1 November 2024
08:15	Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer	businesswire.com
Thursday, 31 October 2024
10:31	Coya Therapeutics: Buying The Dip After Unwarranted Sell-Off	seekingalpha.com
Tuesday, 29 October 2024
14:36	Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study	benzinga.com
06:41	Coya Therapeutics reports positive immune response, safety in mid-stage Alzheimer's drug trial	reuters.com
06:30	Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer's Disease (AD) Presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid (Spain)	businesswire.com
Sunday, 13 October 2024
04:17	Coya Therapeutics Has Several Near-Term Share Price Appreciation Catalysts	seekingalpha.com
Tuesday, 8 October 2024
09:15	Coya Therapeutics Chairman and CEO Howard Berman Selected for PharmaVoice 100	businesswire.com
Friday, 2 August 2024
08:15	Coya Therapeutics Announces that Results from a Double-Blind Placebo-Controlled Study in Alzheimer's Disease will be presented on October 29, 2024 at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid	businesswire.com
Thursday, 20 June 2024
08:15	Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with Funding from the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform into the Clinic	businesswire.com
Tuesday, 11 June 2024
08:15	Coya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology	businesswire.com
Monday, 10 June 2024
14:55	Coya Therapeutics: Potential Milestone For The Treatment Of Alzheimer's This Summer	seekingalpha.com
Monday, 3 June 2024
08:15	Coya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in Neurology	businesswire.com
Tuesday, 28 May 2024
08:15	Coya Therapeutics Announces Inclusion in the MSCI USA Micro Cap Index	businesswire.com
Monday, 27 May 2024
12:32	7 Biotech Stocks to Put on Your Breakthrough Radar	investorplace.com
Thursday, 23 May 2024
15:40	Coya Therapeutics (COYA) CEO on $5M Alzheimer's Drug Discovery Foundation Investment	youtube.com
Wednesday, 22 May 2024
08:15	Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer's Disease	businesswire.com
Monday, 20 May 2024
08:15	Coya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer's Drug Discovery Foundation (ADDF)	businesswire.com
Thursday, 9 May 2024
16:10	Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results	businesswire.com
Wednesday, 1 May 2024
06:45	Why Coya Therapeutics Is A Smart Speculative Buy For Neurodegenerative Diseases	seekingalpha.com
Friday, 26 April 2024
08:15	Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium	businesswire.com
Monday, 22 April 2024
08:15	Coya Therapeutics to Participate in the Mizuho Neuroscience Summit	businesswire.com
Thursday, 18 April 2024
08:15	Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit	businesswire.com
Monday, 8 April 2024
08:15	Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium	Business Wire
Friday, 1 December 2023
08:15	These biotechs targeting multiple neurodegenerative diseases	MarketBeat
Friday, 25 August 2023
09:00	Coya Therapeutics To Present Novel Proof of Concept Exosome Modification Technology at the 5th Exosome Based Therapeutic Development Summit in Boston, MA on September 7, 2023	Business Wire
Monday, 14 August 2023
05:45	Capitalizing On Inflammation's Role In Neurological Disease Part 1: Coya Therapeutics	Seeking Alpha
Wednesday, 7 June 2023
08:40	Coya Therapeutics stock gains on new data from Alzheimer's study	Market Watch

Frequently Asked Questions (FAQ)

What's the price of Coya Therapeutics stock today?

One share of Coya Therapeutics stock can currently be purchased for approximately $5.94.
When is Coya Therapeutics's next earnings date?

Unfortunately, Coya Therapeutics's (COYA) next earnings date is currently unknown.
Does Coya Therapeutics pay dividends?

No, Coya Therapeutics does not pay dividends.
How much money does Coya Therapeutics make?

Coya Therapeutics has a market capitalization of 88.21M. Coya Therapeutics made a loss 7.99M US dollars in net income (profit) last year or -$0.35 on an earnings per share basis.
What is Coya Therapeutics's stock symbol?

Coya Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "COYA".
What is Coya Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Coya Therapeutics?

Shares of Coya Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
How many employees does Coya Therapeutics have?

As Jul 2024, Coya Therapeutics employs 8 workers.
When Coya Therapeutics went public?

Coya Therapeutics, Inc. is publicly traded company for more then 2 years since IPO on 29 Dec 2022.
What is Coya Therapeutics's official website?

The official website for Coya Therapeutics is coyatherapeutics.com.
Where are Coya Therapeutics's headquarters?

Coya Therapeutics is headquartered at 5850 San Felipe Street, Houston, TX.
How can i contact Coya Therapeutics?

Coya Therapeutics's mailing address is 5850 San Felipe Street, Houston, TX and company can be reached via phone at +800 5878170.

Coya Therapeutics, Inc.

coyatherapeutics.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an allogeneic Treg exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company was incorporated in 2020 and is headquartered in Houston, Texas.

+800 5878170

5850 San Felipe Street
Houston, TX 77057

CIK: 0001835022
ISIN: US22407B1089
: